Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed.
about
Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosisEndothelial cells in dengue hemorrhagic feverDiagnosis and treatment of latent infection with Mycobacterium tuberculosisHIV and Tuberculosis: a Deadly Human SyndemicRisk of tuberculosis reactivation with rituximab therapy.A TNF-regulated recombinatorial macrophage immune receptor implicated in granuloma formation in tuberculosis.Mycobacterium avium complex cervical lymphadenitis in an immunocompetent adult.An inflammation loop orchestrated by S100A9 and calprotectin is critical for development of arthritis.Increased pulmonary tumor necrosis factor alpha, interleukin-6 (IL-6), and IL-17A responses compensate for decreased gamma interferon production in anti-IL-12 autovaccine-treated, Mycobacterium bovis BCG-vaccinated mice.HIV-1 and the immune response to TB.The role of the innate immune system in granulomatous disorders.Immunomodulatory drugs: oral and systemic adverse effects.Adjunct immunotherapies for tuberculosis.Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.Immune-mediated diseases: what can be found in the oral cavity?Risk of tuberculosis in patients treated with anti-tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden.Emerging Roles for RIPK1 and RIPK3 in Pathogen-Induced Cell Death and Host Immunity.Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases.Dual mechanism for Mycobacterium tuberculosis cytotoxicity on lung epithelial cells.IL-32 is a molecular marker of a host defense network in human tuberculosis.Phagocytosis and cytokine response to rough and smooth colony variants of Mycobacterium abscessus by human peripheral blood mononuclear cells.Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization.Primary nasal tuberculosis during anti-tumour necrosis factor alpha treatment of a patient with rheumatoid arthritis.Effects and safety of allogenic mesenchymal stem cell intravenous infusion in active ankylosing spondylitis patients who failed NSAIDs: a 20-week clinical trial.Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation.Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis.
P2860
Q21256673-09609E4D-628E-4DAC-B20E-242DD72AF42EQ26825663-110DFF87-1CCD-4F4C-9706-CC84BD8E880EQ27021614-0014C806-40CD-46B4-ADC2-328422BDECDBQ30052157-9979AEA2-4614-4435-8B7D-10626032CC06Q33662445-E6D18A5B-0697-48E2-8E28-946DD166BEF0Q34082666-342D2478-65EF-4DE0-B1C0-5CFD03B912A4Q34150373-610BED60-77E9-4B92-A155-84DD34A44A10Q34429165-150CBB36-90CF-49D6-BFCC-2853E9BCC7A9Q34484151-189C8739-B891-49B3-B44D-2DF3A58DF590Q36815449-511F6081-E7EB-4FC4-8E59-7E2780AE31F2Q36872083-F50BAEE2-7AF3-435F-9425-7A7D92DD740DQ37539743-83314A4E-8268-4EFE-B56C-E75DB31D1990Q37998000-42D2F823-3E58-47AD-890F-22517F334631Q38192553-1386B680-5025-407D-8980-56C5E2F1CE5BQ38290659-BE0BFDB7-C1F3-455D-B3EF-4501A4387DF3Q38306689-301B4BA8-A6F8-4EB7-85B3-074C4350C2D0Q38589407-C6D45479-89B0-4EDA-A451-0B5B3C91DF62Q38635412-6BEDE55C-4552-4382-9181-5B219CC5C734Q39327413-CD7E41FE-7D0A-434A-9446-11253A77C152Q41958265-0D17CBC2-AA38-4937-B33D-106615B9D8D1Q44598135-B647CD84-B641-4860-987D-94848EF1B910Q47258498-9DA90300-ED17-4DB7-AAEF-3D1860EC16ABQ47749372-DD35429F-3511-463B-9F8E-6DBE76126397Q50957540-1458405A-8A74-4B96-8DA9-CC990DB9FAFBQ52881666-5DD315E7-51E3-4D99-94C9-49CF2CD30D2FQ54323036-151364AA-94E2-4A41-8149-AE0FDAB55A10
P2860
Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed.
@en
Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed.
@nl
type
label
Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed.
@en
Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed.
@nl
prefLabel
Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed.
@en
Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed.
@nl
P2860
P921
P356
P1476
Anti-TNF immunotherapy and tuberculosis reactivation: another mechanism revealed.
@en
P2093
Elizabeth A Miller
P2860
P304
P356
10.1172/JCI39143
P407
P50
P577
2009-05-01T00:00:00Z